IQVIA HOLDINGS INC. business relationships
Companies named in IQVIA HOLDINGS INC.’s 10-K filed 2026-02-17, and public companies whose annual reports name IQVIA HOLDINGS INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 14 / 100
Named in IQVIA HOLDINGS INC.’s annual report 3
“The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical res...” SEC filing
“...consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companie...” SEC filing
“...er Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share simila...” SEC filing
Companies whose annual reports name IQVIA HOLDINGS INC. 10
“Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry ("IQVIA"), unless otherwise stated.” SEC filing
“The Peer Group consists of Charles River Laboratories Inc., ICON plc, Medpace Holdings, Inc., IQVIA Holdings Inc. and Thermo Fisher Scientific Inc. The companies in our Peer Group are publicly traded companies that share similar business model characteristics to Fortrea, or provide services to simil...” SEC filing
“Unless otherwise indicated, industry data included in this Item 1 are sourced from IQVIA Holdings Inc. and are for the twelve months ended November 2025 and Viatris product and other company data included in this Item 1 are from internal sources and are as of November 30, 2025.” SEC filing
“We rely on resale data provided by our distributors as well as prescription data provided by Symphony Health and IQVIA in estimating the level of inventory held in the distribution channel.” SEC filing
“accounted for 48.3% of our retail sales in Russia for the 12 months ended March 31, 2026, according to IQVIA data.” SEC filing
“Based on a market report provided by IQVIA Ltd. in 2024, we estimate the total addressable market for our current products, which primarily consists of solutions for biopharmaceutical injectables and in-vitro diagnostic products, to exceed $14 billion in 2025.” SEC filing
“If IQVIA does not successfully carry out their responsibilities under the collaboration agreements or does not perform the specific services we have engaged them to perform to the standard or level we anticipate, the benefits of the strategic collaboration with IQVIA may not be realized and our comm...” SEC filing
“Pursuant to the IQVIA Master Services Agreement, the Company has extended payment terms with respect to a portion of the services provided and has recorded a vendor financing arrangement liability of $ 10.3 million as of December 31, 2025.” SEC filing
“We also intend to partner with IQVIA, pursuant to a Licensing and Services Master Agreement, in the commercialization of CTx-1301,” SEC filing
“in good faith any changes to the services provided by IQVIA due to changes in circumstances or priorities established by us.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.